QIAGEN launches first FDA-approved tissue companion diagnostic to identify the KRAS G12C mutation in NSCLC tumours and expand precision medicine options in lung cancer
QIAGEN has announced the launch of an expanded scope of companion diagnostic (CDx) claims for the therascreen® KRAS RGQ PCR Kit (therascreen KRAS Kit) after it received U.S. regulatory approval as a companion diagnostic to aid in the identification of non-small cell lung cancer (NSCLC) patients that may be eligible for treatment with LUMAKRASTM (sotorasib), a newly approved therapy developed and marketed by Amgen Inc. (AMGN).
Source: selectscience.net
